Postherpetic Neuralgia

• FDA approval · 2026-02-24
  FDA Approved: PREGABALIN — Original Application (FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED)

  FDA approved the original Abbreviated New Drug Application for pregabalin from Fourrts (India) Laboratories Private Limited, granting a gene…

• FDA approval · 2026-02-17
  FDA Approved: GABAPENTIN — Supplemental Application (Creekwood Pharmaceuticals LLC)

  The FDA approved a supplemental application for gabapentin filed by Creekwood Pharmaceuticals LLC.

• FDA approval · 2026-02-12
  FDA Approved: GABAPENTIN — Supplemental Application (Ascend Laboratories, LLC)

  FDA approved a supplemental application for gabapentin by Ascend Laboratories, LLC, updating regulatory approval for this generic product.

• FDA approval · 2026-02-02
  FDA Approved: PREGABALIN — Supplemental Application (Tris Pharma Inc)

  FDA approves Tris Pharma Inc's supplemental application for pregabalin.

• FDA approval · 2026-01-29
  FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)

  FDA granted a supplemental approval for gabapentin submitted by Actavis Pharma, Inc. The action represents a supplemental regulatory action …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2026-01-29
  FDA Approved: GABAPENTIN — Supplemental Application (Rising Pharma Holdings, Inc.)

  FDA approved a supplemental application for Gabapentin from Rising Pharma Holdings, Inc.

• FDA approval · 2026-01-14
  FDA Approved: GABAPENTIN — Supplemental Application (Laurus Labs Limited)

  FDA approved a supplemental application for gabapentin from Laurus Labs Limited (ANDA217965). This action approves the generic product for d…

• FDA approval · 2025-11-24
  FDA Approved: GABAPENTIN — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)

  FDA approved a supplemental application for gabapentin from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (ANDA211314).

• FDA approval · 2025-10-01
  FDA Approved: PREGABALIN — Supplemental Application (Creekwood Pharmaceuticals LLC)

  The FDA approved a supplemental application for pregabalin from Creekwood Pharmaceuticals LLC under ANDA213423.

• FDA approval · 2025-09-19
  FDA Approved: GABAPENTIN — Original Application (ScieGen Pharmaceuticals, Inc.)

  FDA approved ScieGen Pharmaceuticals' original application for a generic gabapentin, enabling a generic version to be marketed for the same …

• FDA approval · 2025-09-17
  FDA Approved: PREGABALIN — Supplemental Application (MARKSANS PHARMA LIMITED)

  The FDA approved a supplemental application for pregabalin from Marksans Pharma Limited, resulting in approval of a generic pregabalin produ…

• FDA approval · 2025-09-05
  FDA Approved: GABARONE — Supplemental Application (INA Pharmaceutics Inc.)

  FDA approved a supplemental application for GABARONE (gabapentin) by INA Pharmaceutics Inc. under ANDA211313. This action typically reflects…

• FDA approval · 2025-08-26
  FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)

  The FDA approved a supplemental application for Gabapentin from Granules Pharmaceuticals Inc. This approval updates the product's labeling/i…

• FDA approval · 2025-08-21
  FDA Approved: PREGABALIN — Supplemental Application (Camber Pharmaceuticals, Inc.)

  FDA approved Camber Pharmaceuticals' supplemental ANDA for pregabalin, authorizing the marketing of a generic pregabalin product.

• FDA approval · 2025-08-21
  FDA Approved: PREGABALIN — Supplemental Application (ScieGen Pharmaceuticals, Inc)

  FDA approved a supplemental application for pregabalin from ScieGen Pharmaceuticals, Inc., confirming approval of the generic product under …

• FDA approval · 2025-08-18
  FDA Approved: PREGABALIN — Supplemental Application (Rising Pharma Holdings, Inc.)

  FDA approved a supplemental application for Pregabalin submitted by Rising Pharma Holdings, Inc. under the approved ANDA.

• FDA approval · 2025-08-15
  FDA Approved: PREGABALIN — Supplemental Application (Indoco Remedies Limited)

  FDA approved a supplemental application for pregabalin from Indoco Remedies Limited, resulting in approval of a generic pregabalin product.

• FDA approval · 2025-08-07
  FDA Approved: GABAPENTIN — Original Application (STALLION LABORATORIES PRIVATE LIMITED)

  The FDA approved Stallion Laboratories Private Limited's Original Application for gabapentin, granting approval of a generic gabapentin prod…

• FDA approval · 2025-07-23
  FDA Approved: GABAPENTIN — Supplemental Application (Camber Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for gabapentin from Camber Pharmaceuticals, enabling the generic version to be marketed.

• FDA approval · 2025-07-21
  FDA Approved: PREGABALIN — Supplemental Application (Alembic Pharmaceuticals Inc.)

  FDA approved Alembic Pharmaceuticals' supplemental application for pregabalin. The approval enables the marketing of a generic pregabalin pr…

• FDA approval · 2025-07-07
  FDA Approved: PREGABALIN — Supplemental Application (Torrent Pharmaceuticals Limited)

  FDA approves a supplemental application for Pregabalin from Torrent Pharmaceuticals Limited, enabling the generic drug to be marketed.

• FDA approval · 2025-07-07
  FDA Approved: PREGABALIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)

  The FDA approved a supplemental application for pregabalin filed by Amneal Pharmaceuticals NY LLC.

• FDA approval · 2025-07-01
  FDA Approved: PREGABALIN CAPSULES, CV — Supplemental Application (Cipla USA Inc.)

  FDA approved a supplemental application for Pregabalin Capsules, CV from Cipla USA Inc., under ANDA to market this generic pregabalin capsul…

• FDA approval · 2025-04-25
  FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)

  The FDA approved a supplemental application for Neurontin (gabapentin) filed by Parke-Davis Div of Pfizer Inc, updating the product labeling…

• FDA approval · 2025-04-25
  FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)

  The FDA approved a supplemental application for Gralise (gabapentin) submitted by Almatica Pharma LLC.